Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program

This is an overview of where and by who this paper has been cited.

Non-profit projects normally ask for donations. We don't. We will survive one way or another. If you wish to help us, please spread the word to let more people use this service.

It is delightful to see our efforts are useful to a broad range of researchers.